Prosecution Insights
Prosecution Insights
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Multi-statute (no §101) | 6 (86%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LALONDE, ALEXANDRA ELIZABETH | 1 | 70.5% | +34.0% |
| BARRERA, IMMACULADA | 1 | 34.6% | +77.3% |
| GILL, RACHEL B | 1 | 65.5% | +27.9% |
| SU-TOBON, QIWEN NMN | 1 | 75.0% | +100.0% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.0% | +16.2% |
| DAHLE, CHUN WU | 1 | 49.8% | +51.4% |
| ZINGARELLI, SANDRA | 1 | 7.4% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 5d overdue |
| 17996127 | BACTERIAL STRAINS FOR USE AS PROBIOTICS, COMPOSITIONS THEREOF, DEPOSITED STRAINS AND METHOD TO IDENTIFY PROBIOTIC BACTERIAL STRAINS | ZINGARELLI, SANDRA | 8d |
| 18546024 | METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY | SU-TOBON, QIWEN NMN | 27d |
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | — |
| 18288115 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | — |
| 18285553 | LENTIVIRAL VECTOR, LENTIVIRAL PARTICLE FOR TREATING HEPATITIS B AND ITS PREPARATION METHOD AND APPLICATION THEREOF | GILL, RACHEL B | — |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 5d overdue |
| 17996127 | BACTERIAL STRAINS FOR USE AS PROBIOTICS, COMPOSITIONS THEREOF, DEPOSITED STRAINS AND METHOD TO IDENTIFY PROBIOTIC BACTERIAL STRAINS | ZINGARELLI, SANDRA | 8d |
| 18546024 | METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY | SU-TOBON, QIWEN NMN | 27d |
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | — |
| 18288115 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | — |
| 18285553 | LENTIVIRAL VECTOR, LENTIVIRAL PARTICLE FOR TREATING HEPATITIS B AND ITS PREPARATION METHOD AND APPLICATION THEREOF | GILL, RACHEL B | — |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1636 | 1 |
| 1672 | 1 |
| 1641 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713519 | MEDICAL DEVICE FOR THE TARGETED APPLICATION OF A THERAPEUTIC AGENT TO THE ROUND WINDOW OF THE COCHLEA | LALONDE, ALEXANDRA ELIZABETH | — | §102§103§112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18288115 | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | BARRERA, IMMACULADA | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18285553 | LENTIVIRAL VECTOR, LENTIVIRAL PARTICLE FOR TREATING HEPATITIS B AND ITS PREPARATION METHOD AND APPLICATION THEREOF | GILL, RACHEL B | 1671 | §102§112 | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18546024 | METHODS AND SYSTEMS FOR GENERATING NUCLEIC ACID DIVERSITY | SU-TOBON, QIWEN NMN | 1636 | §103§112Other | Non-Final OA | 27d | Pending | Aug 10, 2023 |
| 18245987 | HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY | KINSEY WHITE, NICOLE ERIN | 1672 | §102§103 | Non-Final OA | 5d overdue | Pending | Mar 20, 2023 |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | DAHLE, CHUN WU | 1641 | §102§103 | Final Rejection | — | Pending | Mar 14, 2023 |
| 17996127 | BACTERIAL STRAINS FOR USE AS PROBIOTICS, COMPOSITIONS THEREOF, DEPOSITED STRAINS AND METHOD TO IDENTIFY PROBIOTIC BACTERIAL STRAINS | ZINGARELLI, SANDRA | 1653 | §103 | Final Rejection | 8d | Pending | Oct 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial